Published in
American Chemical Society, Journal of Medicinal Chemistry, 14(64), p. 9875-9890, 2021
DOI: 10.1021/acs.jmedchem.0c02081
Links
Tools
First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
Journal article published in 2021 by
Huikai Sun 
,
Holger Monenschein,
Hans H. Schiffer,
Holly A. Reichard,
Shota Kikuchi,
Maria Hopkins,
Todd K. Macklin,
Stephen Hitchcock,
Mark Adams,
Jason Green,
Jason Brown,
Sean T. Murphy,
Nidhi Kaushal,
Deanna R. Collia,
Steve Moore
and other authors.
,
Holger Monenschein,
Hans H. Schiffer,
Holly A. Reichard,
Shota Kikuchi,
Maria Hopkins,
Todd K. Macklin,
Stephen Hitchcock,
Mark Adams,
Jason Green,
Jason Brown,
Sean T. Murphy,
Nidhi Kaushal,
Deanna R. Collia,
Steve Moore
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving allowed
- Must obtain written permission from Editor
- Must not violate ACS ethical Guidelines
Postprint:
archiving restricted
- Must obtain written permission from Editor
- Must not violate ACS ethical Guidelines
Published version:
archiving forbidden
Data provided by 